Sanofi-Aventis acquires insulin sensitiser from Wellstat
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has acquired the exclusive, worldwide licence to develop, manufacture and commercialise Wellstat Therapeutics' insulin sensitiser PN2034 for the treatment of type II diabetes.